BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang GC, Yang TY, Chen KC, Hsu KH, Huang YH, Su KY, Yu SL, Tseng JS. ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients. Sci Rep 2020;10:21063. [PMID: 33273548 DOI: 10.1038/s41598-020-78152-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Fang H, Hong J, Wang X, Wang H, Pan G. Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report. Medicine (Baltimore) 2022;101:e30094. [PMID: 35984185 DOI: 10.1097/MD.0000000000030094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chu C, Huang Y, Lee P, Hsu K, Chen K, Su K, Yu S, Tseng J, Yang T, Chang G. Various impacts of driver mutations on the PD-L1 expression of NSCLC. PLoS ONE 2022;17:e0273207. [DOI: 10.1371/journal.pone.0273207] [Reference Citation Analysis]
3 Bearz A, De Carlo E, Del Conte A, Spina M, Da Ros V, Bertoli E, Revelant A, Stanzione B, Tirelli U. The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation. IJMS 2022;23:7322. [DOI: 10.3390/ijms23137322] [Reference Citation Analysis]
4 Kim SY, Kim T, Park CK, Yoon H, Sa YJ, Kim HR, Woo IS, Kim T. Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives. Cancers 2022;14:3138. [DOI: 10.3390/cancers14133138] [Reference Citation Analysis]
5 Luo Y, Liang K, Huang H, Shen C, Chiang C, Wang M, Chiou S, Chen Y. State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan. IJMS 2022;23:7037. [DOI: 10.3390/ijms23137037] [Reference Citation Analysis]
6 Soo RA, Huat Tan E, Hayashi H, Seto T, Lin C, Ignatius Ou S, Kim D, Liu G, Abbattista A, Martini J, Hooi Wong C, Toffalorio F, Solomon BJ. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.05.012] [Reference Citation Analysis]
7 Peng L, Zhu L, Sun Y, Stebbing J, Selvaggi G, Zhang Y, Yu Z. Targeting ALK Rearrangements in NSCLC: Current State of the Art. Front Oncol 2022;12:863461. [PMID: 35463328 DOI: 10.3389/fonc.2022.863461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yang X, Jiang L, Jin Y, Li P, Hou Y, Yun J, Wu C, Sun W, Fan X, Kuang D, Wang W, Ni J, Mao A, Tang W, Liu Z, Wang J, Xiao S, Li Y, Lin D. PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study. J Cancer 2021;12:7390-8. [PMID: 35003359 DOI: 10.7150/jca.63003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Li M, Hou X, Chen J, Zhang B, Wang N, Han H, Chen L. ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061). Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Seegobin K, Majeed U, Wiest N, Manochakian R, Lou Y, Zhao Y. Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR. Front Oncol 2021;11:750657. [PMID: 34926258 DOI: 10.3389/fonc.2021.750657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Wang S, Luo R, Shi Y, Han X. The impact of the ALK fusion variant on clinical outcomes in EML4-ALK patients with NSCLC: a systematic review and meta-analysis. Future Oncol 2021. [PMID: 34783600 DOI: 10.2217/fon-2021-0945] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
12 Christopoulos P, Dietz S, Angeles AK, Rheinheimer S, Kazdal D, Volckmar AL, Janke F, Endris V, Meister M, Kriegsmann M, Zemojtel T, Reck M, Stenzinger A, Thomas M, Sültmann H. Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies. Transl Lung Cancer Res 2021;10:2118-31. [PMID: 34164264 DOI: 10.21037/tlcr-21-32] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
13 Bozorgmehr F, Kazdal D, Chung I, Kirchner M, Magios N, Kriegsmann M, Allgäuer M, Klotz LV, Muley T, El Shafie RA, Fischer JR, Faehling M, Stenzinger A, Thomas M, Christopoulos P. De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer. Front Oncol 2021;11:640048. [PMID: 33898315 DOI: 10.3389/fonc.2021.640048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Elsayed M, Christopoulos P. Therapeutic Sequencing in ALK+ NSCLC. Pharmaceuticals (Basel) 2021;14:80. [PMID: 33494549 DOI: 10.3390/ph14020080] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]